Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug BHV-1400 tested for kidney disease

NCT ID NCT07054684

Disease control Sponsor: Biohaven Therapeutics Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 participants with confirmed IgA nephropathy will receive the drug subcutaneously. The main goal is to check for side effects and lab abnormalities.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BHV-1400
What this could lead to
If it works, this could point toward a new treatment option for IgA nephropathy, a kidney disease that currently has limited therapies.
What could go wrong
This is a very early Phase 1 trial with only 20 people, focused on safety, not effectiveness. Many drugs fail at this stage, and it may not lead to a real treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1\. Participants must have biopsy-confirmed IgA Nephropathy Key Exclusion Criteria: 1. Any secondary IgAN 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IgA nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome glomerulonephritis IgA glomerulonephritis kidney disorder nephritis proteinuria urinary system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IgA nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    15 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site-001

    RECRUITING

    Farmington, Connecticut, 06030, United States

  • Site-002

    RECRUITING

    Dakota Dunes, South Dakota, 57049, United States

  • Site-003

    RECRUITING

    Miami Lakes, Florida, 33016, United States

  • Site-004

    RECRUITING

    Houston, Texas, 77099, United States

  • Site-005

    RECRUITING

    Pembroke Pines, Florida, 33029, United States

  • Site-006

    RECRUITING

    Chesterfield, Missouri, 63017, United States

  • Site-007

    RECRUITING

    Leicester, LE5 4PW, United Kingdom

  • Site-008

    RECRUITING

    Lawrenceville, Georgia, 30046, United States

  • Site-009

    RECRUITING

    Hinsdale, Illinois, 60521, United States

  • Site-011

    RECRUITING

    Miami Lakes, Florida, 33172, United States

  • Site-012

    RECRUITING

    Indianapolis, Indiana, 46268, United States

  • Site-013

    RECRUITING

    Orlando, Florida, 32806, United States

  • Site-014

    RECRUITING

    Houston, Texas, 77027, United States

  • Site-015

    RECRUITING

    Shelby, Michigan, 48316, United States

  • Site-016

    RECRUITING

    Salt Lake City, Utah, 84115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.